Aclaris Therapeutics, Inc. (ACRS)
6.31
-0.10
(-1.56%)
USD |
NASDAQ |
Aug 24, 16:00
6.34
+0.03
(+0.48%)
Pre-Market: 08:45
Aclaris Therapeutics Net Income (Quarterly) : -21.50M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -21.50M |
| March 31, 2026 | -19.82M |
| December 31, 2025 | -19.80M |
| September 30, 2025 | -14.61M |
| June 30, 2025 | -15.43M |
| March 31, 2025 | -15.08M |
| December 31, 2024 | -96.55M |
| September 30, 2024 | -7.586M |
| June 30, 2024 | -10.99M |
| March 31, 2024 | -16.94M |
| December 31, 2023 | -1.491M |
| September 30, 2023 | -29.26M |
| June 30, 2023 | -29.57M |
| March 31, 2023 | -28.16M |
| December 31, 2022 | -27.64M |
| September 30, 2022 | -19.95M |
| June 30, 2022 | -20.53M |
| March 31, 2022 | -18.79M |
| December 31, 2021 | -22.80M |
| September 30, 2021 | -21.15M |
| June 30, 2021 | -18.16M |
| March 31, 2021 | -28.75M |
| Date | Value |
|---|---|
| December 31, 2020 | -13.60M |
| September 30, 2020 | -10.66M |
| June 30, 2020 | -11.57M |
| March 31, 2020 | -15.33M |
| December 31, 2019 | -19.18M |
| September 30, 2019 | -23.14M |
| June 30, 2019 | -43.68M |
| March 31, 2019 | -27.28M |
| December 31, 2018 | -24.67M |
| September 30, 2018 | -20.63M |
| June 30, 2018 | -31.22M |
| March 31, 2018 | -30.23M |
| December 31, 2017 | -22.93M |
| September 30, 2017 | -18.19M |
| June 30, 2017 | -14.84M |
| March 31, 2017 | -12.56M |
| December 31, 2016 | -11.48M |
| September 30, 2016 | -10.69M |
| June 30, 2016 | -12.87M |
| March 31, 2016 | -13.04M |
| December 31, 2015 | -4.714M |
| September 30, 2015 | -10.63M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Corcept Therapeutics, Inc. | 42.14M |
| Nektar Therapeutics | -40.62M |
| Xeris Biopharma Holdings, Inc. | -31.10M |
| Crinetics Pharmaceuticals, Inc. | -120.86M |
| Alumis, Inc. | -142.22M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 1.629M |
| Total Expenses (Quarterly) | 23.13M |
| EPS Diluted (Quarterly) | -0.1507 |
| Enterprise Value | 792.59M |
| Gross Profit Margin (Quarterly) | 10.80% |
| Profit Margin (Quarterly) | -1.32K% |
| Earnings Yield | -9.27% |
| Normalized Earnings Yield | -9.204 |